抗核抗体(ANA)検査の世界市場予測(~2021年):試薬&検定キット、装置、ソフトウェア、サービス

◆英語タイトル:Antinuclear Antibody Test Market by Product (Reagents & Assay Kits, Systems, Software, Services), Technique (Immunofluorescence, Elisa, Multiplex), Disease (Rheumatoid Arthritis, SLE), End User (Clinical Labs, Hospitals) - Forecast to 2021
◆商品コード:MAM-MD-4588
◆発行会社(調査会社):MarketsandMarkets
◆発行日:2016年9月21日
◆ページ数:167
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥644,100見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥758,100見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥929,100見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarkets社の日本における正規販売代理店です。MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、抗核抗体(ANA)検査の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、製品別分析、技術別分析、疾患別分析、地域別分析、抗核抗体(ANA)検査の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。
【レポートの概要】

The global Antinuclear Antibody Test market is expected to reach USD 1,476.1 Million by 2021 from USD 823.5 Million in 2016, at a CAGR of 12.4%. This market is segmented based on products, diseases, techniques, end users, and regions. On the basis of products, the ANA testing market is segmented into assay kits & reagents, systems, and software & services. The assay kits & reagents segment is expected to account for the largest share of the global market in 2016, primarily due to the growing number of reagent rental agreements and increasing prevalence of autoimmune diseases worldwide.
The antinuclear antibody test market is segmented into five major disease segments, namely, rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, scleroderma, and other diseases. Other diseases include Raynaud’s Syndrome, polymyositis, mixed connective tissue disease, drug-induced lupus, and autoimmune hepatitis. The rheumatoid arthritis segment is expected to account for the largest share of this market primarily due to the increasing incidence of rheumatoid arthritis.

Based on techniques, the ANA testing market is segmented into enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay (IFA), and multiplex assay. The ELISA segment is expected to account for the largest share of this market majorly due to the expanding applications of ANA in autoimmune disease testing and therapeutic drug level monitoring.

The global antinuclear antibody test market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW). North America will continue to dominate the global market in the forecast period. However, Asia is expected to witness the highest growth in the coming years, with the growth in this regional segment centered at China, Japan, and India.

The major players in this market include Alere Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), ERBA Diagnostics, Inc. (U.S.), Trinity Biotech plc (Ireland), Thermo Fisher Scientific, Inc. (U.S.), Antibodies, Inc. (U.S.), EUROIMMUN AG (Germany), Immuno Concepts (U.S.), Inova Diagnostics (U.S.), and Zeus Scientific, Inc. (U.S.).

【レポートの目次】

1 Introduction (Page No. – 17)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 20)
2.1 Secondary Data
2.1.1 Key Data From Secondary Sources
2.2 Primary Data
2.2.1 Key Data From Primary Sources
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Market Breakdown and Data Triangulation
2.5 Assumptions for the Study

3 Executive Summary (Page No. – 28)
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook
3.4 Conclusion

4 Premium Insights (Page No. – 33)
4.1 Antinuclear Antibody Test Market Overview
4.2 Life Cycle Analysis, By Region

5 Market Overview (Page No. – 37)
5.1 Introduction
5.2 Market Segmentation
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 High Incidence of Autoimmune Diseases
5.3.1.2 Increasing Population and Growth in Healthcare Expenditure
5.3.1.3 Growth in the Number of Individuals Covered Under Medical Insurance
5.3.2 Restraints
5.3.2.1 Stringent Regulations for the Approval of Medical Devices
5.3.2.2 Implementation of Excise Duty on Medical Devices in the U.S.
5.3.2.3 Requirement of Significant Capital to Purchase High-Cost Equipment
5.3.3 Opportunities
5.3.3.1 Laboratory Automation
5.3.3.2 Emerging Markets in Asia Present High-Growth Opportunities
5.3.4 Trend
5.3.4.1 Reagent Rental Agreements

6 Antinuclear Antibody Test Market, By Product (Page No. – 47)
6.1 Introduction
6.2 Reagents & Assay Kits
6.3 Systems
6.4 Software & Services

7 Antinuclear Antibody Test Market, By Technique (Page No. – 53)
7.1 Introduction
7.2 Elisa
7.3 Immunofluorescence Assay
7.4 Multiplex Assay

8 Antinuclear Antibody Test Market, By Disease (Page No. – 60)
8.1 Introduction
8.2 Rheumatoid Arthritis
8.3 Systemic Lupus Erythematosus
8.4 Sjögren’s Syndrome
8.5 Scleroderma
8.6 Other Diseases

9 Antinuclear Antibody Test Market, By End User (Page No. – 69)
9.1 Introduction
9.2 Hospitals
9.2.1 Small Hospitals
9.2.2 Mid-Sized Hospitals
9.2.3 Large Hospitals
9.3 Clinical Laboratories
9.4 Physician Office Laboratories
9.5 Other End Users

10 Geographic Analysis (Page No. – 80)
10.1 Introduction
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.4 Asia
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Rest of the Asia (RoA)
10.5 Rest of the World

11 Competitive Landscape (Page No. – 132)
11.1 Introduction
11.2 Strategic Overview
11.3 Market Share Analysis
11.4 Competitive Situation and Trends
11.4.1 Acquisitions
11.4.2 Agreements
11.4.3 New Product Launches
11.4.4 Expansions
11.4.5 Other Developments

12 Company Profiles (Page No. – 138)
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 Introduction
12.2 Thermo Fisher Scientific, Inc.
12.3 Alere Inc.
12.4 Bio-Rad Laboratories, Inc.
12.5 Trinity Biotech PLC
12.6 Erba Diagnostics, Inc.
12.7 Antibodies Inc.
12.8 Euroimmun AG
12.9 Immuno Concepts
12.10 Inova Diagnostics
12.11 Zeus Scientific, Inc.

*Details on Marketsandmarkets View, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix (Page No. – 159)
13.1 Insights of Industry Experts
13.2 Discussion Guide
13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.4 Introducing RT: Real-Time Market Intelligence
13.5 Available Customizations
13.6 Related Reports

List of Tables (73 Tables)

Table 1 Prevalence Data for Autoimmune Diseases
Table 2 High Incidence of Autoimmune Diseases to Drive Market Growth
Table 3 Implementation of Excise Duty on Medical Devices in the U.S. to Restrain Market Growth
Table 4 Growing Demand for Lab Automation to Offer Major Growth Opportunities
Table 5 Reagent Rental Agreements are an Important Trend in the Antinuclear Antibody Test Market
Table 6 Antinuclear Antibody Testing Market Size, By Product, 2014–2021 (USD Million)
Table 7 Antinuclear Antibody Test Market Size for Reagents & Assay Kits, By Region, 2014–2021 (USD Million)
Table 8 Antinuclear Antibody Test Market Size for Systems, By Region, 2014–2021 (USD Million)
Table 9 Antinuclear Antibody Test Market Size for Software & Services, By Region, 2014–2021 (USD Million)
Table 10 Antinuclear Antibody Testing Market Size, By Technique, 2014–2021 (USD Million)
Table 11 Antinuclear Antibody Test Market Size for Elisa, By Region, 2014–2021 (USD Million)
Table 12 Antinuclear Antibody Test Market Size for Ifa, By Region, 2014–2021 (USD Million)
Table 13 Antinuclear Antibody Test Market Size for Multiplex Assays, By Region, 2014–2021 (USD Million)
Table 14 Antinuclear Antibody Test Market Size, By Disease, 2014–2021 (USD Million)
Table 15 Market Size for Rheumatoid Arthritis, By Region, 2014–2021 (USD Million)
Table 16 Market Size for Systemic Lupus Erythematosus, By Region, 2014–2021 (USD Million)
Table 17 Market Size for Sjögren’s Syndrome, By Region, 2014–2021 (USD Million)
Table 18 Market Size for Scleroderma, By Region, 2014–2021 (USD Million)
Table 19 Market Size for Other Diseases, By Region, 2014–2021 (USD Million)
Table 20 Antinuclear Antibody Test Market Size, By End User, 2014–2021 (USD Million)
Table 21 Global Antinuclear Antibody Test Market Size for Hospitals, By Type, 2014–2021 (USD Million)
Table 22 Market Size for Hospitals, By Region, 2014–2021 (USD Million)
Table 23 Market Size for Small Hospitals, By Region, 2014–2021 (USD Million)
Table 24 Market Size for Mid-Sized Hospitals, By Region, 2014–2021 (USD Million)
Table 25 Market Size for Large Hospitals, By Region, 2014–2021 (USD Million)
Table 26 Market Size for Clinical Laboratories, By Region, 2014–2021 (USD Million)
Table 27 Market Size for Physician Office Laboratories, By Region, 2014–2021 (USD Million)
Table 28 Market Size for Other End Users, By Region, 2014–2021 (USD Million)
Table 29 Market Size, By Region, 2014–2021 (USD Million)
Table 30 North America: Market Size, By Country, 2014–2021 (USD Million)
Table 31 North America: Market Size, By Product, 2014–2021 (USD Million)
Table 32 North America: Market Size, By Technique, 2014–2021 (USD Million)
Table 33 North America: Market Size, By Disease, 2014–2021 (USD Million)
Table 34 North America: Market Size, By End User, 2014–2021 (USD Million)
Table 35 U.S.: Market Size, By Product, 2014–2021 (USD Million)
Table 36 U.S.: Market Size, By Technique, 2014–2021 (USD Million)
Table 37 U.S.: Market Size, By End User, 2014–2021 (USD Million)
Table 38 Canada: Market Size, By Product, 2014–2021 (USD Million)
Table 39 Canada: Market Size, By Technique, 2014–2021 (USD Million)
Table 40 Canada: Market Size, By End User, 2014–2021 (USD Million)
Table 41 Europe: Market Size, By Country, 2014–2021 (USD Million)
Table 42 Europe: Market Size, By Product, 2014–2021 (USD Million)
Table 43 Europe: Market Size, By Technique, 2014–2021 (USD Million)
Table 44 Europe: Market Size, By Disease, 2014–2021 (USD Million)
Table 45 Europe: Market Size, By End User, 2014–2021 (USD Million)
Table 46 Asia: Market Size, By Country, 2014–2021 (USD Million)
Table 47 Asia: Market Size, By Product, 2014–2021 (USD Million)
Table 48 Asia: Market Size, By Technique, 2014–2021 (USD Million)
Table 49 Asia: Market Size, By Disease, 2014–2021 (USD Million)
Table 50 Asia: Market Size, By End User, 2014–2021 (USD Million)
Table 51 China: Market Size, By Product, 2014–2021 (USD Million)
Table 52 China: Market Size, By Technique, 2014–2021 (USD Million)
Table 53 China: Market Size, By End User, 2014–2021 (USD Million)
Table 54 Japan: Market Size, By Product, 2014–2021 (USD Million)
Table 55 Japan: Market Size, By Technique, 2014–2021 (USD Million)
Table 56 Japan: Market Size, By End User, 2014–2021 (USD Million)
Table 57 India: Market Size, By Product, 2014–2021 (USD Million)
Table 58 India: Market Size, By Technique, 2014–2021 (USD Million)
Table 59 India: Market Size, By End User, 2014–2021 (USD Million)
Table 60 RoA: Market Size, By Product, 2014–2021 (USD Million)
Table 61 RoA: Market Size, By Technique, 2014–2021 (USD Million)
Table 62 RoA: Market Size, By End User, 2014–2021 (USD Million)
Table 63 RoW: Market Size, By Country, 2014–2021 (USD Million)
Table 64 RoW: Market Size, By Product, 2014–2021 (USD Million)
Table 65 RoW: Market Size, By Technique, 2014–2021 (USD Million)
Table 66 RoW: Market Size, By Disease, 2014–2021 (USD Million)
Table 67 RoW: Market Size, By End User, 2014–2021 (USD Million)
Table 68 Growth Strategy Matrix, 2013–2016
Table 69 Acquisitions, 2013–2016
Table 70 Agreements, 2013–2016
Table 71 New Product Launches, 2013–2016
Table 72 Expansions, 2013–2016
Table 73 Other Developments, 2013–2016


List of Figures (102 Figures)

Figure 1 Market Segmentation
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Antinuclear Antibody Test Market: Bottom-Up Approach
Figure 5 Antinuclear Antibody Test Market: Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Global Antinuclear Antibody Test Market Size, By Product, 2016 vs 2021 (USD Million)
Figure 8 Global Antinuclear Antibody Test Market Size, By Technique, 2016 vs 2021 (USD Million)
Figure 9 Global Antinuclear Antibody Test Market Size, By Disease Type, 2016 vs 2021 (USD Million)
Figure 10 Global Antinuclear Antibody Test Market Size, By End User, 2016 vs 2021 (USD Million)
Figure 11 Global Antinuclear Antibody Test Market Size, By Region, 2016 vs 2021 (USD Million)
Figure 12 Global Antinuclear Antibody Test Market to Witness Moderate Growth During the Forecast Period
Figure 13 Hospitals Segment to Dominate the Global ANA Testing Market in 2016
Figure 14 Asia Projected to Witness the Fastest Growth During the Forecast Period (2016-2021)
Figure 15 Asian Market Showcases Lucrative Growth Opportunities
Figure 16 Antinuclear Antibody Testing Market Segmentation
Figure 17 ANA Testing Market: Drivers, Restraints, Opportunities, & Trends
Figure 18 Global Population Data (2010–2015), in Billion
Figure 19 Global Healthcare and Public Healthcare Spending, 2010-2015
Figure 20 Growth in Healthcare Expenditure, By Region
Figure 21 Reagents & Assay Kits to Form the Largest Product Segment in 2016
Figure 22 North America to Dominate the Antinuclear Antibody Test Market for Reagents & Assay Kits in 2016
Figure 23 North America to Dominate the Antinuclear Antibody Test Market for Systems in 2016
Figure 24 North America to Dominate the Antinuclear Antibody Test Market for Software & Services in 2016
Figure 25 Elisa Technique to Dominate the Antinuclear Antibody Testing Market in 2016
Figure 26 North America to Dominate the Antinuclear Antibody Test Market for Elisa in 2016
Figure 27 North America to Dominate the Antinuclear Antibody Test Market for Immunofluorescence Assay in 2016
Figure 28 North America to Dominate the Antinuclear Antibody Test Market for Multiplex Assays in 2016
Figure 29 Rheumatoid Arthritis to Dominate the Antinuclear Antibody Testing Market, By Disease, in 2016
Figure 30 North America to Dominate the Market for Rheumatoid Arthritis in 2016
Figure 31 North America to Dominate the Market for Systemic Lupus Erythematosus in 2016
Figure 32 North America to Dominate the Market for Sjögren’s Syndrome in 2016
Figure 33 North America to Dominate the Market for Scleroderma in 2016
Figure 34 North America to Dominate the Market for Other Diseases in 2016
Figure 35 Antinuclear Antibody Testing Market Size, By End User, 2016 (USD Million)
Figure 36 Global Antinuclear Antibody Testing Market Size for Hospitals, By Type, 2016 (USD Million)
Figure 37 North America to Dominate the Market for Hospitals in 2016
Figure 38 North America to Dominate the Market for Small Hospitals in 2016
Figure 39 North America to Dominate the Market for Mid-Sized Hospitals in 2016
Figure 40 North America to Dominate the Market for Large Hospitals in 2016
Figure 41 North America to Dominate the Market for Clinical Laboratories in 2016
Figure 42 North America to Dominate the Market for Physician Office Laboratories in 2016
Figure 43 North America to Dominate the Market for Other End Users in 2016
Figure 44 Global Economic Indicators (2005–2014)
Figure 45 Geographic Snapshot of the Antinuclear Antibody Testing Market
Figure 46 ANA Testing Market, By Region (Market Size and Growth Rate)
Figure 47 North America: Economic Indicators (2005–2014)
Figure 48 North America: Antinuclear Antibody Market Snapshot, 2016
Figure 49 North America: ANA Testing Market, By Country (Market Size and Growth Rate)
Figure 50 Reagents & Assay Kits to Account for the Largest Share of the Antinuclear Antibody Test Market in North America in 2016
Figure 51 Elisa Technique to Account for the Largest Share of the Antinuclear Antibody Test Market in 2016
Figure 52 Rheumatoid Arthritis to Account for the Largest Share of the Antinuclear Antibody Test Market in 2016
Figure 53 Hospitals to Account for the Largest Share of the ANA Testing Markets in 2016
Figure 54 U.S.: Economic Indicators (2005–2014)
Figure 55 Reagents & Assay Kits to Account for the Largest Share in 2016
Figure 56 Elisa Technique to Account for the Largest Share of the ANA Testing Market in 2016
Figure 57 Hospitals to Dominate the ANA Testing Market in 2016
Figure 58 Canada: Economic Indicators (2005–2014)
Figure 59 Reagents & Assay Kits to Account for the Largest Share in 2016
Figure 60 Elisa Technique to Account for the Largest Share of the ANA Testing Market in 2016
Figure 61 Hospitals to Dominate the ANA Testing Market in 2016
Figure 62 Europe: Economic Indicators (2005–2014)
Figure 63 Europe: ANA Testing Market, By Country (Market Size and Growth Rate)
Figure 64 Reagents & Assay Kits to Account for the Largest Share of the ANA Testing Market in 2016
Figure 65 Elisa Technique to Account for the Largest Share of the ANA Testing Market in 2016
Figure 66 Rheumatoid Arthritis to Account for the Largest Share of the ANA Testing Market in 2016
Figure 67 Hospitals to Dominate the ANA Testing Market in 2016
Figure 68 Asia: Economic Indicators (2005–2014)
Figure 69 Asia: Antinuclear Antibody Market Snapshot, 2016
Figure 70 Asia: ANA Testing Market, By Country (Market Size and Growth Rate)
Figure 71 Reagents & Assay Kits to Account for the Largest Share of the ANA Testing Market in 2016
Figure 72 Elisa Technique to Account for the Largest Share of the ANA Testing Market in 2016
Figure 73 Rheumatoid Arthritis to Account for the Largest Share of the ANA Testing Market in 2016
Figure 74 Hospitals to Dominate the ANA Testing Market in 2016
Figure 75 China: Economic Indicators (2005–2014)
Figure 76 Reagents & Assay Kits to Account for the Largest Share in 2016
Figure 77 Elisa Technique to Account for the Largest Share of the ANA Testing Market in 2016
Figure 78 Hospitals to Dominate the ANA Testing Market in 2016
Figure 79 Japan: Economic Indicators (2005–2014)
Figure 80 Reagents & Assay Kits to Account for the Largest Share in 2016
Figure 81 Elisa Technique to Account for the Largest Share of the ANA Testing Market in 2016
Figure 82 Hospitals to Dominate the ANA Testing Market in 2016
Figure 83 India: Economic Indicators (2005–2014)
Figure 84 Reagents & Assay Kits to Account for the Largest Share in 2016
Figure 85 Elisa Technique to Account for the Largest Share of the Market in 2016
Figure 86 Hospitals to Dominate the Market in 2016
Figure 87 Reagents & Assay Kits to Account for Largest Share in 2016
Figure 88 Elisa Technique to Account for the Largest Share of the Market in 2016
Figure 89 Hospitals to Dominate the Market in 2016
Figure 90 RoW: Market, By Country (Market Size and Growth Rate)
Figure 91 Reagents & Assay Kits to Account for the Largest Share of the Market in 2016
Figure 92 Elisa Technique to Account for the Largest Share of the Market in 2016
Figure 93 Rheumatoid Arthritis to Account for the Largest Share of the Market in 2016
Figure 94 Hospitals to Dominate the Market in 2016
Figure 95 New Product Launches, Acquisitions, and Agreements—Key Growth Strategies Adopted By Players in the Market
Figure 96 Market Share Analysis, By Key Player, 2014
Figure 97 Financial Performances of the Leading Market Players
Figure 98 Thermo Fisher Scientific, Inc.: Company Snapshot
Figure 99 Alere Inc.: Company Snapshot
Figure 100 Bio-Rad Laboratories, Inc.: Company Snapshot
Figure 101 Trinity Biotech PLC: Company Snapshot
Figure 102 Erba Diagnostics, Inc.: Company Snapshot

【レポートのキーワード】

抗核抗体(ANA)、抗核抗体検査、抗核抗体検査試薬、検定キット、抗核抗体検査装置、抗核抗体検査ソフトウェア、サービス、抗核抗体検査技術、疾患、医療機器、関節リウマチ、全身性エリテマトーデス

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[抗核抗体(ANA)検査の世界市場予測(~2021年):試薬&検定キット、装置、ソフトウェア、サービス]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月11日現在 219,328 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆